X-ray diffraction analysis of a human immunodeficiency virus (HIV-1) capsid (CA) protein shows that each monomer within the dimer consists of seven alpha-helices, five of which are arranged in a coiled coil-like structure. Sequence assignments were made for two of the helices, and tentative connectivity of the remainder of the protein was confirmed by the recent solution structure of a monomeric N-terminal fragment. The C-terminal third of the protein is mostly disordered in the crystal. The longest helices in the coiled coil-like structure are separated by a long, highly antigenic peptide that includes the binding site of an antibody fragment complexed with CA in the crystal. The site of binding of the Fab, the position of the antigenic loop and the site of cleavage between the matrix protein and CA establish the side of the dimer that would be on the exterior of the retroviral core.
This report examines structural changes in a highly mutated, clinical multidrug-resistant HIV-1 protease, and the crystal structure has been solved to 1.3 A resolution in the absence of any inhibitor. This protease variant contains codon mutations at positions 10, 36, 46, 54, 62, 63, 71, 82, 84, and 90 that confer resistance to protease inhibitors. Major differences between the wild-type and the variant include a structural change initiated by the M36V mutation and amplified by additional mutations in the flaps of the protease, resulting in a "wide-open" structure that represents an opening that is 8 A wider than the "open" structure of the wild-type protease. A second structural change is triggered by the L90M mutation that results in reshaping the 23-32 segment. A third key structural change of the protease is due to the mutations from longer to shorter amino acid side chains at positions 82 and 84.
The goal of this study was to use X-ray crystallography to investigate the structural basis of resistance to human immunodeficiency virus type 1 (HIV-1) protease inhibitors. We overexpressed, purified, and crystallized a multidrug-resistant (
Aquifex aeolicus, an organism that flourishes at 95°C, is one of the most thermophilic eubacteria thus far described. The A. aeolicus pyrB gene encoding aspartate transcarbamoylase (ATCase) was cloned, overexpressed in Escherichia coli, and purified by affinity chromatography to a homogeneous form that could be crystallized. Chemical cross-linking and size exclusion chromatography showed that the protein was a homotrimer of 34-kDa catalytic chains. The activity of A. aeolicus ATCase increased dramatically with increasing temperature due to an increase in k cat with little change in the K m for the substrates, carbamoyl phosphate and aspartate. The K m for both substrates was 30 -40-fold lower than the corresponding values for the homologous E. coli ATCase catalytic subunit. Although rapidly degraded at high temperature, the carbamoyl phosphate generated in situ by A. aeolicus carbamoyl phosphate synthetase (CPSase) was channeled to ATCase. The transient time for carbamoyl aspartate formation was 26 s, compared with the much longer transient times observed when A. aeolicus CPSase was coupled to E. coli ATCase. Several other approaches provided strong evidence for channeling and transient complex formation between A. aeolicus ATCase and CPSase. The high affinity for substrates combined with channeling ensures the efficient transfer of carbamoyl phosphate from the active site of CPSase to that of ATCase, thus preserving it from degradation and preventing the formation of toxic cyanate.Aquifex aeolicus, one of the most hyperthermophilic eubacteria thus far discovered, is classified as a hydrogen-oxidizing, microaerophilic, obligate chemolithoautotroph (1). This marine organism is related to the filamentous bacteria isolated from the hot springs in Yellowstone near the turn of the last century (2, 3). One intriguing question is how unstable metabolites are preserved from thermal degradation in A. aeolicus and other hyperthermophiles. For example, carbamoyl phosphate, a key intermediate in both pyrimidine and arginine biosynthetic pathways, has a half-life of less than 2 s at 100°C and decomposes to toxic cyanate, a promiscuous alkylating agent (4, 5).In the pyrimidine biosynthetic pathway, carbamoyl phosphate is used as a substrate, along with aspartate, for the formation of carbamoyl aspartate in a reaction catalyzed by aspartate transcarbamoylase (ATCase 1 ; EC 2.1.3.2).Carbamoyl phosphate ϩ aspartate 3 carbamoyl aspartate ϩ P i REACTION 1
Darunavir and tipranavir are two inhibitors that are active against multi-drug resistant (MDR) HIV-1 protease variants. In this study, the in vitro inhibitory efficacy was tested against a MDR HIV-1 protease variant, MDR 769 82T, containing the drug resistance mutations of 46L/54V/82T/84V/90M. Crystallographic and enzymatic studies were performed to examine the mechanism of resistance and the relative maintenance of potency. The key findings are as follows: (i) The MDR protease exhibits decreased susceptibility to all nine HIV-1 protease inhibitors approved by the U.S. Food and Drug Administration (FDA), among which darunavir and tipranavir are the most potent; (ii) the threonine 82 mutation on the protease greatly enhances drug resistance by altering the hydrophobicity of the binding pocket; (iii) darunavir or tipranavir binding facilitates closure of the wide-open flaps of the MDR protease; and (iv) the remaining potency of tipranavir may be preserved by stabilizing the flaps in the inhibitor-protease complex while darunavir maintains its potency by preserving protein main chain hydrogen bonds with the flexible P2 group. These results could provide new insights into drug design strategies to overcome multi-drug resistance of HIV-1 protease variants.
Point mutations and inserts in the 3-4 region of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) are associated with resistance to nucleoside analog inhibitors. This report describes HIV-1 strains from seven patients that were found to have a 3-bp deletion in the 3-4 region of the RT gene. These patient strains also had a mean of 6.2 drug resistance-associated mutations in their RT genes (range, 3 to 10 mutations). The deletion was most frequently found in strains with the Q151M mutation. Nonnucleoside RT inhibitor mutations were found in six of seven strains. Culture-based drug sensitivity assays showed that deletion-containing isolates had reduced susceptibility to four to eight RT inhibitors. Site-directed mutagenesis experiments showed that the deletion alone conferred reduced susceptibility to nucleoside analogs. Changes in the threedimensional models of the RT deletion mutants were consistently observed at the 3-4 loop and at helices C and E in both the presence and the absence of dTTP. Loss of hydrogen bonds between the RT and dTTP were also observed in the RT deletion mutant. These results suggest that the deletion in the RT gene contributes to resistance to several nucleoside analogs through a complex interaction with other mutations in the RT gene.Treatment of human immunodeficiency virus type 1 (HIV-1)-infected individuals with combinations of protease and reverse transcriptase (RT) inhibitors has been highly effective in increasing both their duration and quality of life (3). Strong adherence to these treatment regimens often reduces the plasma virus concentrations to below the limits of detection by currently available assays. Treatment failure, typically defined as a significant rise from previously suppressed levels of circulating virus, is often associated with the emergence of virus strains resistant to antiretroviral drugs (7).Mutations in the protease and RT genes of HIV-1 have been shown to confer resistance to antiretroviral drugs (compiled in reference 23). For protease inhibitors and nonnucleoside RT inhibitors (nnRTI), a relatively limited number of mutations provide resistance to all members of each respective class. Resistance mutations selected by nucleoside RT inhibitors (nRTI) are generally drug specific and provide limited cross-resistance to other nRTI. However, patients may have virus strains resistant to many nRTI through either the accumulation of many drug-specific mutations or the acquisition of unique multidrug resistance mutations.A substantial number of mutations conferring resistance to nRTI have been demonstrated to appear in the 3-4 region (codons 62 to 78) of HIV-1 RT (18,23,29). Point mutations associated with reduced drug susceptibility have been demonstrated at codons 62, 65, 67, 69, 70, 74, 75, and 77 (2, 6, 14, 27). In addition, an insert between codons 69 and 70 has recently been shown to participate in resistance to multiple nucleoside analogs (5,16,32). This insert pattern, along with the Q151M complex of mutations (24, 26), compri...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.